{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06780670\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PSMAcTION","nct_id":"NCT06780670","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=psmaction-nct06780670. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PSMAcTION","arms":[{"description":"AAA817 will be given for a number of cycles; a cycle = 8 weeks","label":"Phase II: AAA817 Dose B","type":"EXPERIMENTAL"},{"description":"Participants will be given Standard of Care (SOC) treatment per Investigator's choice.","label":"Phase III: Investigator's choice of SoC","type":"ACTIVE_COMPARATOR"},{"description":"AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks","label":"Phase II: AAA817 Dose A","type":"EXPERIMENTAL"},{"description":"Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks","label":"Phase III: Recommended Phase 3 Dose of AAA817","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2033-07-19","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":443,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Investigators choice of SoC","otherNames":[],"type":"DRUG"},{"name":"AAA817","otherNames":["[225Ac]Ac-PSMA-617)"],"type":"DRUG"},{"name":"AAA817","otherNames":["[225Ac]Ac-PSMA-617)"],"type":"DRUG"},{"name":"AAA817","otherNames":["[225Ac]Ac-PSMA-617"],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Novartis Pharmaceuticals","official_title":"PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-06-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Biochemical response rate (Phase II)","timeFrame":"from date of randomization up to approximately 24 months"},{"measure":"Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II","timeFrame":"from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later"},{"measure":"Tolerability of the proposed dose of AAA817- Phase II","timeFrame":"From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817"},{"measure":"Radiographic progression-free survival (rPFS)- Phase III","timeFrame":"from date of randomization up to approximately 24 months"},{"measure":"Overall survival (OS)- Phase III","timeFrame":"from date of randomization up to approximately 24 months"}],"references":[],"start_date":{"date":"2025-02-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","url":"https://clinicaltrials.gov/study/NCT06780670"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/psmaction-nct06780670"}